Press release
Leading Companies Enhancing Their Presence in the Shingrix (Zostavax) Market
Shingrix (Zostavax) Market
Forecasted Market Size and Growth Drivers in the Shingrix (Zostavax) Industry
The anticipated expansion of the Shingrix (Zostavax) market through 2030 is driven by several important factors. Increasing targets for adult vaccination coverage and greater healthcare spending focused on preventive care are key contributors. The development and broadening of recombinant vaccine pipelines also play a crucial role, supported by government-backed immunization initiatives aimed at increasing access. Additionally, there is a growing emphasis on minimizing the burden of post-herpetic neuralgia, a painful complication of shingles, which further fuels demand for effective vaccines.
Download a free sample of the shingrix (zostavax) market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20264&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Expanding Recombinant Vaccine Adoption and Safety Emphasis
A notable trend shaping this market is the rising adoption of recombinant vaccine platforms, which are gaining favor due to their safety and efficacy profiles. Adult immunization programs are becoming increasingly prioritized, reflecting a shift toward long-term protection against shingles. Innovations in cold-chain optimized vaccine distribution systems are improving accessibility, especially in regions with challenging logistics. Throughout this period, enhanced focus on vaccine safety and performance is expected to remain a top priority for manufacturers and healthcare providers alike.
Leading Industry Players Driving the Shingrix (Zostavax) Market Forward
GSK plc stands out as a major player in the Shingrix (Zostavax) market. A significant development occurred in October 2023 when GSK plc partnered with Chongqing Zhifei, a prominent China-based biotechnology firm specializing in vaccine development and distribution. This collaboration is designed to broaden Shingrix's reach in China, the world's second-largest pharmaceutical market by expenditure. GSK plc, headquartered in the UK, continues to manufacture and market Shingrix, positioning itself strongly within this growing sector.
View the full shingrix (zostavax) market report:
https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Innovations and Product Launches Influencing Market Dynamics
The Shingrix (Zostavax) market is marked by a focus on creating novel vaccines that are safer and more effective, particularly to address immune system declines related to aging and to serve immunocompromised individuals. Recombinant subunit adjuvanted vaccines-those that include specific pathogen proteins combined with an immune-boosting adjuvant-are gaining traction as alternatives to traditional live-attenuated vaccines. For example, in 2023, GSK plc introduced Shingrix (Recombinant Zoster Vaccine, RZV) in India. This non-live vaccine, administered intramuscularly over two doses, contains the glycoprotein E antigen alongside GSK's proprietary AS01B adjuvant system. Shingrix is known for inducing a strong, long-lasting immune response with efficacy rates approaching 97%, effectively countering immunity decline in older adults.
Market Segmentation and Distribution Patterns in the Global Shingrix (Zostavax) Market
This report divides the Shingrix (Zostavax) market into key segments for a thorough analysis. These include formulation types, such as recombinant vaccines (Shingrix) and live attenuated vaccines (Zostavax). The market is also categorized based on indication, covering shingles prevention and post-herpetic neuralgia treatment. Distribution channels are classified into hospital pharmacies and retail pharmacies, reflecting diverse avenues for vaccine delivery to patients worldwide.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leading Companies Enhancing Their Presence in the Shingrix (Zostavax) Market here
News-ID: 4494611 • Views: …
More Releases from The Business Research Company
In-Depth Examination of Segments, Industry Trends, and Key Competitors in the Te …
A closer look at the Tenivac market reveals a promising outlook driven by several key factors shaping its expansion through 2030. With increasing attention on long-term immunization strategies and a growing emphasis on vaccinating adult and elderly populations, this sector is poised for steady growth. Advancements in vaccine technology and stronger global efforts to prevent diseases are further fueling market development.
Significant investments in vaccine infrastructure are playing a crucial role…
Analysis of Key Market Segments Influencing the Waylivra Market
An in-depth look at the Waylivra market reveals a sector poised for significant growth, driven by advancements in genetic medicine and personalized treatment approaches. As the demand for targeted therapies and rare disease management rises, the market is evolving with new partnerships and expanding applications. This overview explores the market size, key drivers, major players, and segmentations shaping the future of Waylivra.
Projected Market Value Growth of the Waylivra Industry by…
Vowst Market Overview: Major Segments, Strategic Developments, and Leading Compa …
The Vowst market is gaining significant attention as advances in microbiome-based therapies reshape approaches to infection management and gut health. With rising investments and evolving treatment technologies, this market is set for notable growth over the coming years. Let's explore the current market size, leading players, key trends, and detailed segment insights shaping the future of Vowst.
Projected Expansion and Growth Factors in the Vowst Market
The growth anticipated in…
Competitive Landscape: Key Market Leaders and Rising Contenders in the Taltz Mar …
Understanding the future of autoimmune treatment options reveals significant growth potential for the Taltz market. As personalized therapies gain traction and biologic innovations advance, this sector is set for promising developments. Here's an in-depth look at the projected market size, key players, ongoing trends, and important segments within the Taltz industry.
Projected Market Size and Growth Factors in the Taltz Market
The Taltz market is expected to expand substantially by…
More Releases for Shingrix
Shingles Vaccines Market (2026-2033) | Recombinant Vaccines, Adult Vaccines, Shi …
DataM Intelligence has released a new research report titled "Shingles Vaccines Market Size 2026" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms…
Shingrix (Zostavax) Market Forecast 2025-2034: Comprehensive Analysis And Growth …
"We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Projected Growth of the Shingrix (Zostavax) Market?
In the past few years, the Shingrix (Zostavax) market has seen a growth of XX (HCAGR). The market, which was worth $XX million in 2024, is projected to further grow to $XX million in 2025, implying a compound annual growth rate (CAGR)…
In-Depth Analysis of the Shingrix Zostavax Market: Growth Opportunities, Key Tre …
What industry-specific factors are fueling the growth of the shingrix zostavax market?
The Shingrix (Zostavax) market is also set to grow, driven by the increasing adoption of vaccination globally. Growing awareness of the effectiveness of vaccination in preventing diseases, combined with public health initiatives and improved healthcare infrastructure, is boosting vaccination rates. Shingrix, which protects against shingles, is particularly important for adults over 50, reducing the risk of shingles recurrence and…
In-Depth Analysis of the Shingrix (Zostavax) Market: Growth Opportunities, Key T …
What Are the Projected Growth and Market Size Trends for the Shingrix (Zostavax) Market?
The market size for shingrix (zostavax) has seen an increase of $XX (CAGR) in the latest years. The market is expected to surge from $XX million in 2024 to $XX million in 2025, indicating a compound annual growth rate (CAGR) of $XX%. The growth seen in the previous period is due to factors such as enhanced vaccine…
Shingles Vaccine Market Demand Will Reach a Value of USD 6.02 Billion by the Yea …
Anticipated Growth in Revenue:
Shingles Vaccine Market was valued at USD 3.06 Billion in 2022, and it is expected to reach USD 6.02 Billion by 2029, exhibiting a CAGR of 10.1 % during the forecast period (2023-2029)
Shingles Vaccine Market Overview:
The Shingles Vaccine Market is witnessing significant growth due to the increasing awareness of the severe complications associated with shingles, such as postherpetic neuralgia (PHN). Shingrix, a recombinant zoster vaccine, has become…
Shingles Vaccines Market Size, Share, Industry, Forecast and outlook (2024-2031)
Shingles Vaccines Market
Shingles Vaccines Market Anticipates Robust Growth with a Projected CAGR of 10.00% from 2024 to 2031
The global Shingles Vaccines Market is poised for substantial expansion, estimated to achieve a Compound Annual Growth Rate (CAGR) of 10.00% during the forecast period spanning from 2023 to 2030.
Recommended in established nations such as the US, Canada, Germany, and the UK, the shingles vaccine is integral to National Immunisation Programs (NIP) in…
